ALT vs. SIGA, CMPS, IGMS, OLMA, ABUS, AVTE, YMAB, HROW, APLT, and KALV
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include SIGA Technologies (SIGA), COMPASS Pathways (CMPS), IGM Biosciences (IGMS), Olema Pharmaceuticals (OLMA), Arbutus Biopharma (ABUS), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Harrow (HROW), Applied Therapeutics (APLT), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Altimmune (NASDAQ:ALT) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
Altimmune has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
SIGA Technologies has a net margin of 50.48% compared to Altimmune's net margin of -22,645.37%. SIGA Technologies' return on equity of 51.97% beat Altimmune's return on equity.
Altimmune received 44 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 70.00% of users gave Altimmune an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote.
Altimmune currently has a consensus price target of $17.25, suggesting a potential upside of 115.36%. Given Altimmune's higher probable upside, equities analysts plainly believe Altimmune is more favorable than SIGA Technologies.
SIGA Technologies has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Altimmune had 17 more articles in the media than SIGA Technologies. MarketBeat recorded 29 mentions for Altimmune and 12 mentions for SIGA Technologies. Altimmune's average media sentiment score of 0.30 beat SIGA Technologies' score of -0.05 indicating that Altimmune is being referred to more favorably in the media.
78.1% of Altimmune shares are owned by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are owned by institutional investors. 4.1% of Altimmune shares are owned by company insiders. Comparatively, 2.2% of SIGA Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Altimmune beats SIGA Technologies on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altimmune Competitors List
Related Companies and Tools
